STIMHealthcare · Medical DevicesThe 4 Wall Street analysts covering Neuronetics, Inc. hold a median 12-month price target of $5.5 — +150.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Neuronetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Volatility (7): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on STIM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +150.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Sept 2026 | BTIG | Reiterates | Buy | — |
| 17 Sept 2026 | BTIG | Reiterates | Buy | $6.00 |
| 11 Sept 2026 | B. Riley Securities | Initiates | Buy | $5.00 |
| 11 Sept 2026 | B. Riley Securities | Initiates | Buy | — |
| 9 Sept 2026 | BTIG | Reiterates | Buy | $6.00 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | — |
| 11 Aug 2026 | BTIG | Maintains | Buy | — |
| 11 Aug 2026 | BTIG | Maintains | Buy | $5.00 → $6.00 |
| 20 July 2026 | BTIG | Initiates | Buy | — |
| 20 July 2026 | BTIG | Initiates | Buy | $5.00 |
| 19 Mar 2026 | Canaccord Genuity | Maintains | Buy | $7.00 → $3.00 |
| 19 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 14 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 12 Aug 2024 | William Blair | Downgrade | Market Perform | — |
| 14 May 2024 | William Blair | Upgrade | Outperform | — |
| 6 Mar 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
STIM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Neuronetics, Inc. returned −18.5% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 66% of US stocks
Cheaper than 9% of US stocks
Cheaper than 87% of US stocks
Higher than 50% of US stocks
Higher than 48% of US stocks
Higher than 63% of US stocks
Higher than 28% of US stocks
Higher than 16% of US stocks
Higher than 12% of US stocks
Higher than 26% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Neuronetics, Inc. has a market value of $181.3M and an enterprise value of $252.5M.
Revenue in the twelve months to 30 June 2026: $155.1M. The latest quarter grew 9.1% year on year.
Net income over the same four quarters: −$30.8M, a −19.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.44.
Free cash flow in the twelve months to 30 June 2026: −$11.3M.
Trailing P/E: −3.7×; forward P/E: −6.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Neuronetics, Inc. employs 658 people — $236K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Neuronetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Neuronetics announced it plans to release its third-quarter 2026 financial and operating results before market open on November 4, 2026.
Why it matters — STIM watchers can note the scheduled date for the company’s quarterly results and operating update.
Neuronetics announced the integration of its TrakStar practice management platform with AdvancedMD, a cloud-based EHR, practice management, and revenue cycle platform serving more than 65,000 practitioners across 13,000 independent practices. This marks the first-ever TMS integration with an EHR/EMR system.
Why it matters — The integration could streamline practice workflows for NeuroStar TMS users and potentially expand the technology's adoption across a large base of independent mental-health practices.
Neuronetics, Inc. published its Q2 2026 earnings call transcript on Seeking Alpha, covering the company's second-quarter financial results and management discussion.
Why it matters — A STIM watcher would care because the transcript provides the company's official quarterly update, including its financial performance and commentary.
Neuronetics reported second-quarter 2026 revenue growth, a sharply narrower net loss, and positive adjusted EBITDA, driven by expansion of its Greenbrook clinic business and new commercial purchasing options for its NeuroStar TMS systems.
Why it matters — The financial results show improved operational performance and growing adoption of the company's core TMS therapy platform.
Neuronetics (STIM) reported a second-quarter loss of $0.05 per share, which was narrower than the Zacks Consensus Estimate of a $0.11 loss and an improvement from a $0.15 per share loss in the prior-year quarter.
Why it matters — A smaller-than-expected quarterly loss indicates improved financial performance versus analyst expectations and the year-ago period, which STIM watchers would track closely.
The 4 Wall Street analysts covering Neuronetics, Inc. have a median 12-month price target of $5.5, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Neuronetics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neuronetics, Inc. 63 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Neuronetics, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +150.0% from the last close, and Ticker Nerd's factor model ranks Neuronetics, Inc. 63 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Neuronetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.
Neuronetics, Inc. returned -18.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments.
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call". Neuronetics announced it plans to release its third-quarter 2026 financial and operating results before market open on November 4, 2026.
Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments. Its core offering is the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation platform used primarily for adult patients with major depressive disorder. The company also provides related treatment sessions and support services, serving psychiatric practices and mental health providers in the United States and international markets. Neuronetics operates at the intersection of medical devices and clinic services, combining device commercialization with patient care delivery. Its products are designed to expand access to non-drug therapeutic options for psychiatric and neurological conditions, making the company a significant participant in the neuromodulation market.
CEO Mr. Daniel L. Reuvers · 658 employees · United States · https://neurostar.com/neuronetics
